Selzentry® (maraviroc tablets)
Prior Authorization Criteria

Selzentry (maraviroc 150mg and 300mg tablets) will be restricted for use in combination with other antiretroviral agents for the treatment of adults infected with CCR5-tropic HIV-1.

Approval Criteria:

1. Clinically diagnosed HIV-1 infection
2. Age greater than 16 years
3. Exclusively CCR5-tropic virus verified by a trophile or other validated assay for determining HIV tropism

Test results must be provided in order to meet approval criteria and ensure appropriate use.

Approval will be given for a 12-month period.